Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
نویسندگان
چکیده
Sigrid Carlsson, Memorial Sloan-Kettering Cancer Center, New York, NY; Sahlgrenska Academy at Göteborg University, Göteborg, Sweden Andrew J. Vickers, Memorial Sloan-Kettering Cancer Center, New York, NY Monique Roobol, Erasmus Medical Center, Rotterdam, the Netherlands James Eastham and Peter Scardino, Memorial Sloan-Kettering Cancer Center, New York, NY Hans Lilja, Memorial Sloan-Kettering Cancer Center, New York, NY; Lund University, Malmö, Sweden; and Institute of Biomedical Technology, University of Tampere, Tampere, Finland Jonas Hugosson, Sahlgrenska Academy at Göteborg University, Göteborg, Sweden
منابع مشابه
Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries.
F or clinical evidence to have an impact on the health of populations, guideline recommendations must be rapidly and widely disseminated and physicians and other health care professionals must act responsively. Recommendations to discontinue care may be even more challenging. Recently, the US Preventive Services Task Force (USPSTF) recommended that no man receives prostate-specific antigen (PSA...
متن کاملPsychological research and the prostate-cancer screening controversy.
In October of 2011, the U.S. Preventive Services Task Force released a draft report in which they recommended against using the prostate-specific antigen (PSA) test to screen for prostate cancer. We attempt to show that four factors documented by psychological research can help explain the furor that followed the release of the task force's report. These factors are the persuasive power of anec...
متن کاملNew US Preventive Service Task Force recommendations for prostate cancer screening: a needed update, but not enough
DOI: 10.1590/S1679-45082017ED4151 Prostate cancer (PC) screening remains a controversial topic, although it has been studied for more than two decades. Since the 1990s, when the use of ProstateSpecific Antigen (PSA) began in clinical practice, the mortality rate from PC has decreased by around 50%. Prostate cancer screening policies, early diagnosis and treatment are pointed out as responsible ...
متن کاملScreening for prostate cancer with prostate-specific antigen. An examination of the evidence.
In October 2011, the U.S. Preventive Services Task Force (USPSTF, or "Task Force") released draft recommendations on prostate cancer screening with prostate-specific antigen (PSA), concluding that "PSA-based screening results in small or no reduction in prostate cancer-specific mortality and is associated with harms related to subsequent evaluation and treatments, some of which may be unnecessa...
متن کاملThe United States Preventive Services Task Force recommendation against prostate-specific antigen screening--counterpoint.
As aprostate cancer expert, I amdisturbed by the recent U.S. Preventive Services Task Force (USPSTF) draft recommendation against prostate cancer screening in asymptomatic men (1) and hope to clarify information from recent studies on this issue. Implementation of the USPSTF draft recommendation has the potential to cause great harm. Prostate cancer is a leading cause of cancer death, and count...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
دوره 30 21 شماره
صفحات -
تاریخ انتشار 2012